Oxaliplatin, folinic acid and 5-fluorouracil (OFF) in patients with recurrent advanced head and neck cancer: A phase II feasibility study

Oral Oncology

Volumn 42, Issue 6, 2006, Pages 614-618

  Raguse, Jan Dirk ^a   Gath, Hans Joachim ^a   Oettle, Helmut ^a   Bier, Jürgen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

5 Fluorouracil; Advanced head neck tumours; Folinic acid; Oxaliplatin

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; QUALITY OF LIFE; RECURRENCE; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 33745644000     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2005.11.001     Document Type: Article

References (26)

1. Rapidis A.D., Keramidas T., Panagiotopoulos H., Andressakis D., and Angelopoulos A.P. Tumours of the head and neck in the elderly: analysis of 190 patients. J Craniomaxillofac Surg 26 3 (1998) 153-158
2. Jacobs C., Lyman G., Velez Garcia E., et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous carcinoma of the head and neck. J Clin Oncol 10 2 (1992) 257-263
3. Glisson B.S., Murphy B.A., Frenette G., Khuri F.R., and Forastiere A.A. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 20 6 (2002) 1593-1599
4. Garcia-Carbonero R., Hitt R., Castellano D., et al. Phase II trial of cisplatin (C) and gemcitabine (G) in advanced squamous cell carcinoma of the head and neck (AHNC). Proc Am Soc Clin Oncol 17 (1998) 151
5. Vokes E.E., Weichselbaum R.R., Lippman S.M., and Hong W.K. Head and neck cancer. N Engl J Med 328 3 (1993) 184-194
6. Campbell J.B., Dorman E.B., McCormick M., et al. A randomized phase III trial of cisplatinum, methotrexate, cisplatinum + methotrexate, and cisplatinum + 5-fluoro-uracil in end-stage head and neck cancer. Acta Otolaryngol 103 5-6 (1987) 519-528
7. Liverpool Head and Neck Oncology Group. A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 61 2 (1990) 311-315 Erratum in: Br J Cancer 1990;62(1):171
8. Schantz S.P., Harrison L.B., and Hong W.K. Cancer of the head and neck. In: De Vita V.T., Hellmann S., and Rosenberg S.A. (Eds). Cancer principles and practice of oncology (1993), JB Lippincott Company, Philadelphia 579-589
9. Forastiere A.A., and Urba S.G. Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin Oncol 22 3 Suppl. 6 (1995) 24-27
10. Catimel G., Verweij J., Mattijssen V., et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck: EORTC Early Clinical Trials Group. Ann Oncol 5 6 (1994) 533-537
11. Vokes E.E., Choi K.E., Schilsky R.L., Moran W.J., Guarnieri C.M., Weichselbaum R.R., et al. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol 6 4 (1988) 618-626
12. Dreyfuss A.I., Clark J.R., Wright J.E., Norris Jr. C.M., Busse P.M., Lucarini J.W., et al. Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med 112 3 (1990) 167-172
13. Pfister D.G., Bajorin D., Motzer R., Scher H., Louison C., Harrison L., et al. Increased toxicity without improved response in squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg 120 1 (1994) 89-95
14. Hoff P.M., and Fuchs C.S. The experience with oxaliplatin in the treatment of upper gastrointestinal carcinomas. Semin Oncol 30 4 Suppl. 15 (2003) 54-61
15. Becouarn Y., Agostini C., Trufflandier N., and Boulanger V. Oxaliplatin: available data in non-colorectal gastrointestinal malignancies. Crit Rev Oncol Hematol 40 3 (2001) 265-272
16. Espinosa M., Martinez M., Aguilar J.L., Mota A., De la Garza J.G., Maldonado V., et al. Oxaliplatin activity in head and neck cancer cell lines. Cancer Chemother Pharmacol 55 3 (2005) 301-305 E-pub.: 21 October 2004
17. Forastiere A.A., Metch B., Schuller D.E., et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexat in advanced squamous-cell carcinoma of the head and neck: a southwest oncology group study. J Clin Oncol 10 (1992) 1245-1251
18. Kaye S.B. New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 78 3 (1998) 1-7
19. Adamo V., Ferraro G., Pergolizzi S., Sergi C., Laudani A., Settineri N., et al. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol 40 5 (2004) 525-531
20. Khuri F.R., Shin D.M., Glisson B.S., Lippman S.M., and Hong W.K. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Semin Oncol 27 4 Suppl. 8 (2000) 25-33
21. Misset J.L., Bleiberg H., Sutherland W., Bekradda M., and Cvitkovic E. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 35 2 (2000) 75-93
22. Cassidy J. Review of oxaliplatin: an active platinum agent in colorectal cancer. Int J Clin Pract 54 6 (2000) 399-402
23. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 23 (2004) 2343-2351
24. Grothey A., and Sargent D.J. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. J Clin Oncol 23 15 (2005) 3311-3313
25. Degardin M., Cappelaere P., Krakowski I., Fargeot P., Cupissol D., and Brienza S. Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol 32 4 (1996) 278-279
26. Louvet C., Andre T., Tigaud J.M., Gamelin E., Douillard J.Y., Brunet R., et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20 23 (2002) 4543-4548